Company intelligence / Profile preview
Draig Therapeutics
Cardiff, Wales, United Kingdomdraigtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Draig’s lead candidate, DT‑101, is a positive allosteric modulator of the AMPA receptor. It has demonstrated safety, tolerability, and target engagement in Phase 1 trials. The company is initiating Phase 2 studies for MDD in 2025. Two additional highly selective GABA(_A) modulators are advancing toward clinical trials by 2026. The company’s approach aims to address large unmet needs in neuropsychiatry with differentiated small molecules targeting core neurotransmitter systems.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Cardiff University / Medicines Discovery InstituteSV Health InvestorsICG Life Sciences
Beyond the preview
Go deeper on Draig Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Draig Therapeutics.